IDNA - ETF AI Analysis

Top Page

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA)

Rating:57Neutral

Price Target:―

The iShares Genomics Immunology and Healthcare ETF (IDNA) has a moderate overall rating, reflecting a mix of strengths and challenges among its holdings. Strong contributors like Incyte and Merck stand out due to their robust financial performance, strategic R&D focus, and reasonable valuations, which support the fund's rating. However, weaker holdings such as Celcuity and Revolution Medicines, both facing financial challenges and bearish trends, weigh down the overall score. A key risk factor for this ETF is its concentration in the biotech sector, which is inherently volatile and dependent on clinical and financial milestones.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid returns so far this year, indicating strong momentum in its holdings.

Global Diversification

While primarily focused on the U.S., the fund also includes exposure to other regions like Europe and Asia, adding geographic diversity.

Reasonable Expense Ratio

The ETF's expense ratio is relatively low compared to many specialized funds, helping investors keep more of their returns.

Negative Factors

Sector Concentration

The fund is heavily concentrated in the healthcare sector, which could make it vulnerable to industry-specific risks.

Underperforming Holdings

Some top holdings, such as Regeneron and Merck, have shown weak performance this year, which could drag on overall returns.

Small Asset Base

The ETF has relatively low assets under management, which could lead to higher trading costs and less liquidity for investors.

IDNA vs. SPDR S&P 500 ETF (SPY)

AUM138.04M

RegionGlobal

Expense Ratio0.47%

Beta0.91

IssueriShares

Inception DateJun 11, 2019

Dividend Yield1.12%

Asset ClassEquity

Index TrackedNYSE FactSet Global Genomics and Immuno Biopharma Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume37,660

30 Day Avg. Volume32,664

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

34.83

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering49

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IDNA Summary

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an investment fund that focuses on companies leading advancements in genomics, immunology, and healthcare. It includes businesses working on cutting-edge technologies like gene editing, genome sequencing, and personalized medicine. Some of its top holdings are well-known healthcare companies like Regeneron and AstraZeneca. Investors might consider IDNA for its potential long-term growth in the rapidly evolving healthcare and biotechnology sectors. However, it’s important to know that this ETF is heavily focused on healthcare, meaning its performance can be affected by changes in that industry or regulatory challenges.

How much will it cost me?The iShares Genomics Immunology and Healthcare ETF (IDNA) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires active management to track innovative companies in genomics and healthcare. The higher cost reflects the specialized nature of the fund.

What would affect this ETF?The IDNA ETF, focused on genomics and healthcare innovation, could benefit from advancements in gene editing, personalized medicine, and increased global healthcare spending, which may drive growth in its top holdings like Revolution Medicines and Regeneron. However, it faces risks from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector, which could impact the performance of companies within the fund. Global economic conditions and changes in government healthcare policies could also influence the ETF's future performance.

IDNA Top 10 Holdings

The IDNA ETF is heavily concentrated in healthcare, with a global mix of companies driving innovation in genomics and immunology. Regeneron is a steady performer, buoyed by strong revenue growth and strategic investments, while Celcuity is rising fast thanks to its promising clinical pipeline despite early-stage risks. Moderna’s mixed performance reflects declining revenues but strong technical momentum, and BeiGene is lagging with bearish trends and valuation concerns. Overall, the fund’s focus on cutting-edge biotech and healthcare innovation positions it for long-term growth, though some holdings face hurdles.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
RVMD	Revolution Medicines	5.65%	$7.86M	$20.76B	157.04%	52 Neutral
MRNA	Moderna	4.70%	$6.53M	$13.23B	-19.86%	59 Neutral
BAYN	Bayer	4.44%	$6.17M	€38.20B	94.02%	54 Neutral
4502	Takeda Pharmaceutical Co	4.33%	$6.02M	¥8.05T	24.63%	66 Neutral
REGN	Regeneron	4.21%	$5.85M	$83.72B	14.94%	78 Outperform
MRK	Merck & Company	4.21%	$5.85M	$274.34B	11.83%	80 Outperform
ROG	Roche Holding AG	4.18%	$5.82M	CHF272.24B	45.48%	73 Outperform
	―	4.09%	$5.69M	―	―	―
GSK	GlaxoSmithKline	3.97%	$5.53M	£76.08B	39.76%	77 Outperform
IPN	Ipsen	3.96%	$5.51M	€10.54B	7.74%	70 Outperform

IDNA Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

26.15

Positive

100DMA

24.73

Positive

200DMA

22.59

Positive

Market Momentum

MACD

0.28

Negative

RSI

61.92

Neutral

STOCH

88.76

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDNA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.54, equal to the 50-day MA of 26.15, and equal to the 200-day MA of 22.59, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 61.92 is Neutral, neither overbought nor oversold. The STOCH value of 88.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDNA.

IDNA Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IDNA	―	―	$138.04M	0.47%	―
IVES	―	―	$996.66M	0.75%	―
BUG	―	―	$950.03M	0.51%	―
IHAK	―	―	$850.99M	0.47%	―
NUKZ	―	―	$771.27M	0.85%	―
PBW	―	―	$761.07M	0.64%	―

Performance Comparison

IDNA

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund

27.82

6.54

30.73%

IVES

Dan IVES Wedbush AI Revolution ETF

―

BUG

Global X Cybersecurity Etf

―

IHAK

iShares Cybersecurity & Tech ETF

―

NUKZ

Range Nuclear Renaissance Index ETF

―

PBW

Invesco WilderHill Clean Energy ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents